Pharming Group (NL:PHARM)
:PHARM
Want to see NL:PHARM full AI Analyst Report?
PHARM Stock Chart & Stats
€1.61
-€0.03(-3.69%)
At close: 4:00 PM EST
€1.61
-€0.03(-3.69%)
Day’s Range― - ―
52-Week Range€0.69 - €1.82
Previous CloseN/A
Volume8.99M
Average Volume (3M)19.18M
Market Cap
€1.08B
Enterprise Value€1.21B
Total Cash (Recent Filing)€179.88M
Total Debt (Recent Filing)€115.79M
Price to Earnings (P/E)347.8
Beta1.07
Next Earnings
May 07, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding706,252,300
10 Day Avg. Volume15,825,784
30 Day Avg. Volume19,178,179
Financial Highlights & Ratios
PEG Ratio-2.75
Price to Book (P/B)3.72
Price to Sales (P/S)2.64
P/FCF Ratio20.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.02
Revenue Forecast (FY)€405.15M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsConsistently very high gross margins reflect strong product economics and meaningful pricing power common in specialty biologics. These margins provide durable cash generation to fund R&D, commercialization and patient support programs, cushioning the business against volume swings.
Improving Balance SheetDeclining leverage and a growing equity base increase financial flexibility and reduce refinancing risk. A healthier balance sheet supports sustained funding for clinical programs, geographic expansion and potential M&A without immediate dependence on dilutive financing.
Return To Positive Cash FlowResumption of positive operating and free cash flow in 2025 shows the business can generate internal funding for operations and investment. Alignment between cash flow and reported earnings enhances funding sustainability for commercialization and pipeline activities.
Bears Say
Revenue & Profit VolatilityMaterial swings in revenue and profitability over recent years reduce predictability and complicate long-term planning. Volatility can hinder consistent reinvestment in commercial expansion and clinical development, and increases execution risk for multi-year initiatives.
Thin Operating/Net MarginsDespite high gross margins, limited conversion to operating and net income leaves earnings fragile. Thin margins make the company highly sensitive to cost inflation, commercial setbacks or payer pressure, constraining retained cash for growth and reducing resilience.
Product Concentration & Payer RiskRevenue concentration in two rare-disease therapies creates dependency on small patient populations, diagnosis rates and reimbursement. This structural concentration amplifies execution and reimbursement risk and limits scalability absent successful new indications or product launches.
Pharming Group News
PHARM FAQ
What was Pharming Group’s price range in the past 12 months?
Pharming Group lowest stock price was €0.69 and its highest was €1.82 in the past 12 months.
What is Pharming Group’s market cap?
Pharming Group’s market cap is €1.08B.
When is Pharming Group’s upcoming earnings report date?
Pharming Group’s upcoming earnings report date is May 07, 2026 which is in 19 days.
How were Pharming Group’s earnings last quarter?
Pharming Group released its earnings results on Mar 12, 2026. The company reported €0.006 earnings per share for the quarter, beating the consensus estimate of €0.002 by €0.004.
Is Pharming Group overvalued?
According to Wall Street analysts Pharming Group’s price is currently Overvalued.
Does Pharming Group pay dividends?
Pharming Group does not currently pay dividends.
What is Pharming Group’s EPS estimate?
Pharming Group’s EPS estimate is 0.
How many shares outstanding does Pharming Group have?
Pharming Group has 706,252,300 shares outstanding.
What happened to Pharming Group’s price movement after its last earnings report?
Pharming Group reported an EPS of €0.006 in its last earnings report, beating expectations of €0.002. Following the earnings report the stock price went down -3.423%.
Which hedge fund is a major shareholder of Pharming Group?
Currently, no hedge funds are holding shares in NL:PHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pharming Group
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
PHARM Company Deck
PHARM Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance with significant revenue growth and upgraded guidance. RUCONEST and Joenja both showed robust performance, and the company's cash position has been restored. However, there is a planned withdrawal of RUCONEST from certain markets due to financial sustainability concerns. Overall, the positive aspects significantly outweigh the lowlight.View all NL:PHARM earnings summariesTechnical Analysis
Options Prices
Currently, No data available
---